Irena Loryan
Researcher at Institutionen för farmaci; Translationell PKPD
- Telephone:
- +46 18 471 49 95
- E-mail:
- irena.loryan@farmbio.uu.se
- Visiting address:
- Biomedicinskt Centrum BMC, Husargatan 3
752 37 Uppsala - Postal address:
- Box 580
751 23 UPPSALA
Download contact information for Irena Loryan at Institutionen för farmaci; Translationell PKPD
Researcher at Institutionen för farmaci; Translationell PKPD
- E-mail:
- irena.loryan@farmaci.uu.se
- Visiting address:
- Biomedicinskt Centrum BMC, Husargatan 3
752 37 Uppsala - Postal address:
- Box 580
751 23 UPPSALA
Download contact information for Irena Loryan at Institutionen för farmaci; Translationell PKPD
Researcher at Institutionen för farmaci; Translationell PKPD
- Visiting address:
- Biomedicinskt Centrum BMC, Husargatan 3
752 37 Uppsala - Postal address:
- Box 580
751 23 UPPSALA
Download contact information for Irena Loryan at Institutionen för farmaci; Translationell PKPD
- ORCID:
- 0000-0002-1557-4416
More information is available to staff who log in.
Keywords
- blood-brain barrier
- blood-csf barrier
- blood-dorsal root ganglia barrier
- blood-nerve barrier
- brain drug delivery
- cns barriers
- neurodegeneration
- neuropharmacokinetics
Biography
Associate Professor (Docent) Irena Loryan is a Senior Lecturer in the translational Pharmacokinetics-Pharmacodynamics (tPKPD) group in the Department of Pharmacy, Uppsala University, Sweden. She received her M.D. in 2001 and Ph.D. in pharmacology and biochemistry in 2007 from Yerevan State Medical University, Armenia. She then from 2008 to 2011 worked as a post-doctoral fellow at the Division of Pharmacogenetics at the Department of Pharmacology and Physiology, Karolinska Institutet (Prof. Magnus Ingelman-Sundberg Lab). From 2011 to 2013, she worked as a post-doctoral fellow at the Department of Pharmaceutical Biosciences, Uppsala University (Prof. Margareta Hammarlund-Udenaes Lab) in collaboration with Janssen Pharmaceutica, Beerse, Belgium. Since 2013 she has been a researcher and since 2021 a PI in the tPKPD group. Her current research interest focuses on neuropharmacokinetics, implying a mechanistic understanding of drug disposition in central and peripheral nervous systems involving passage across CNS and PNS barriers, distribution within parenchyma and elimination processes in health and disease.
Publications
Selection of publications
- Unbound Brain-to-Plasma Partition Coefficient, K-p,K-uu,K-brain-a Game Changing Parameter for CNS Drug Discovery and Development (2022)
- Neuropharmacokinetic visualization of regional and subregional unbound antipsychotic drug transport across the blood-brain barrier. (2021)
- Heterogeneous drug tissue binding in brain regions of rats, Alzheimer’s patients and controls (2019)
- In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions (2016)
- Molecular properties determining unbound intracellular and extracellular brain exposure of CNS drug candidates (2015)
- Mechanistic Understanding of Brain Drug Disposition to Optimize the Selection of Potential Neurotherapeutics in Drug Discovery (2014)
- The brain slice method for studying drug distribution in the CNS (2013)
Recent publications
- Analysis of the contributing role of drug transport across biological barriers in the development and treatment of chemotherapy-induced peripheral neuropathy (2024)
- Neurofilament light chain in plasma as a sensitive diagnostic biomarker of peripheral neurotoxicity (2023)
- Active Uptake of Oxycodone at Both the Blood-Cerebrospinal Fluid Barrier and The Blood-Brain Barrier without Sex Differences (2023)
- Differential Blood-Brain Barrier Transport and Cell Uptake of Cyclic Peptides In Vivo and In Vitro (2023)
- Pharmacokinetics of Novel Dopamine Transporter Inhibitor CE-123 and Modafinil with a Focus on Central Nervous System Distribution (2023)
All publications
Articles
- Analysis of the contributing role of drug transport across biological barriers in the development and treatment of chemotherapy-induced peripheral neuropathy (2024)
- Neurofilament light chain in plasma as a sensitive diagnostic biomarker of peripheral neurotoxicity (2023)
- Active Uptake of Oxycodone at Both the Blood-Cerebrospinal Fluid Barrier and The Blood-Brain Barrier without Sex Differences (2023)
- Differential Blood-Brain Barrier Transport and Cell Uptake of Cyclic Peptides In Vivo and In Vitro (2023)
- Pharmacokinetics of Novel Dopamine Transporter Inhibitor CE-123 and Modafinil with a Focus on Central Nervous System Distribution (2023)
- Brain barriers virtual (2022)
- Unbound Brain-to-Plasma Partition Coefficient, K-p,K-uu,K-brain-a Game Changing Parameter for CNS Drug Discovery and Development (2022)
- Professor Margareta Hammarlund-Udenaes - Humbled Scientist Shaping Modern Neuropharmacokinetics (2022)
- Neuropharmacokinetic visualization of regional and subregional unbound antipsychotic drug transport across the blood-brain barrier. (2021)
- Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis (2020)
- Heterogeneous drug tissue binding in brain regions of rats, Alzheimer’s patients and controls (2019)
- Amorphisation of Free Acid Ibuprofen and Other Profens in Mixtures with Nanocellulose (2019)
- Mechanistic Study on the Use of the L-Type Amino Acid Transporter 1 for Brain Intracellular Delivery of Ketoprofen via Prodrug (2019)
- Rate and extent of mitragynine and 7-hydroxymitragynine blood-brain barrier transport and their intra-brain distribution (2019)
- Quantitative Assessment of Drug Delivery to Tissues and Association with Phospholipidosis (2017)
- In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions (2016)
- Molecular properties determining unbound intracellular and extracellular brain exposure of CNS drug candidates (2015)
- Effect of transporter inhibition on the distribution of cefadroxil in rat brain (2014)
- Mechanistic Understanding of Brain Drug Disposition to Optimize the Selection of Potential Neurotherapeutics in Drug Discovery (2014)
- Sex difference in formation of propofol metabolites (2013)
- The brain slice method for studying drug distribution in the CNS (2013)
- UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems (2012)
- Influence of sex on propofol metabolism, a pilot study (2012)
- Dual behavior of cyclic peptides at the blood-brain barrier vs brain cellular uptake: Importance for CNS drug development
- Cellular uptake and intra-brain distribution of cyclic cell penetrating peptides: why tissue and cell type matters